Medically Reviewed Content
Written by Rob Anderson, Health Technology Researcher & Medical Content Specialist. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting any medication.
Kidney health is one of the most important yet underappreciated areas where semaglutide shows benefit. For years, the question was whether GLP-1 medications were safe for people with chronic kidney disease. The FLOW trial answered that question — and went much further than expected.
The FLOW Trial: A Landmark Result
The FLOW trial enrolled 3,533 adults with type 2 diabetes and chronic kidney disease (eGFR 50–75 or eGFR 25–75 with elevated urine albumin). Participants received semaglutide 1mg weekly or placebo, plus standard care. Results published in 2024 showed semaglutide reduced the composite kidney outcome (sustained 50% eGFR reduction, kidney failure, or kidney/cardiovascular death) by 24% compared to placebo. The trial was stopped early due to overwhelming benefit. This makes semaglutide the first GLP-1 receptor agonist with proven kidney-protective effects in a dedicated outcomes trial.
How Semaglutide Protects Kidneys
Multiple mechanisms are likely at work. Improved glycaemic control reduces glycation damage to kidney filtration units (glomeruli) — chronic high blood sugar is the primary driver of diabetic kidney disease. Blood pressure reduction decreases the mechanical stress on glomerular capillaries. Weight loss reduces hyperfiltration — the kidneys of obese individuals are chronically overworked. Direct GLP-1 receptor activation in kidney tissue appears to reduce inflammation and oxidative stress independent of metabolic improvements.
For People Without Kidney Disease
In people with normal kidney function (eGFR above 60 with no proteinuria), semaglutide does not harm the kidneys at standard doses. The main kidney-related risk is dehydration during early weeks if nausea/vomiting is significant — dehydration reduces renal blood flow and can temporarily raise creatinine. Staying well hydrated, especially during the titration phase, protects kidney function.
Monitoring Guidance
If you have known CKD, request baseline and follow-up renal function tests (eGFR, creatinine, urine albumin-to-creatinine ratio) before and during semaglutide treatment. Share the FLOW trial data with your nephrologist or GP — many are not yet aware of the full implications for prescribing in CKD. Monitor hydration closely during titration weeks.
Frequently Asked Questions
Q: Is Ozempic safe for kidneys?
A: Yes — semaglutide is generally considered kidney-safe and may actually be beneficial for kidney health. The FLOW trial (2024) tested semaglutide specifically in people with type 2 diabetes and chronic kidney disease, showing a 24% reduction in the risk of major kidney outcomes including kidney failure, sustained eGFR decline, and kidney or cardiovascular death. Semaglutide is the first GLP-1 medication with a dedicated kidney outcomes trial showing benefit.
Q: Does Ozempic improve kidney function?
A: In people with type 2 diabetes and chronic kidney disease (CKD), semaglutide slows kidney disease progression. The FLOW trial demonstrated significant reduction in kidney failure events. Mechanisms include: reduced kidney inflammation, improved glycaemic control (high blood sugar directly damages kidneys), reduced blood pressure, and weight loss reducing the mechanical burden on kidney filtration. In people with normal kidney function, semaglutide does not appear to harm the kidneys at standard doses.
Q: Should I avoid Ozempic if I have kidney disease?
A: Mild-to-moderate CKD (eGFR above 15) is generally not a contraindication to semaglutide and may be an indication given the FLOW trial data. Severe CKD or dialysis requires specialist input. Importantly, during periods of significant nausea/vomiting-driven dehydration on semaglutide, kidney function can be temporarily affected — staying well hydrated is essential. Discuss your specific kidney function with your prescribing physician before starting.
📖 Further Reading
Start Semaglutide With Full Medical Oversight
Physician monitoring ensures kidney and metabolic health throughout treatment.
Sponsored | Affiliate link
Affiliate disclosure: Affiliate links present. See our Affiliate Disclosure.
Ready to Start GLP-1 Treatment?
Compare our top-rated online providers — all physician-supervised, no insurance needed.
Sponsored links – we may earn a commission at no cost to you